logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11634493 B1

PDFFull Text
Date of Patent:
Apr. 25, 2023

Filed:

Nov. 02, 2017

Tumor immunotherapy target and application thereof

Applicant:

Beijing Proteome Research Center, Beijing, CN;

Inventors:

Li Tang, Beijing, CN;

Fuchu He, Beijing, CN;

Di Liu, Beijing, CN;

Qian Lu, Beijing, CN;

Assignee:

BEIJING PROTEOME RESEARCH CENTER, Beijing, CN;

Attorney:

Scully, Scott, Murphy & Presser, P.C.

Primary Examiner:

Ilia I Ouspenski

Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 19/00 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61P 35/02 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2827 (2013.01); A61P 35/02 (2018.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01);
Abstract

The present invention provides a tumor immunotherapy target and use thereof, specifically provides use of the LSECtin expressed by infiltrating tumor-associated macrophage and BTN3A3 expressed by tumor solely or in combination as a target in tumor immunotherapy, and further provides a substance capable of inhibiting the activity of LSECtin expressed by infiltrating tumor-associated macrophage, the activity of BTN3A3 expressed by tumor, or the interaction of the LSECtin with BTN3A3, including RNA molecules, fusion protein BTN3A3-Ig, and monoclonal antibody 5E08, which can be used as an active ingredient to prepare a tumor immunotherapy drug, and is suitable for industrial applications.

Find Patent Forward Citations

Tang, Li. (2023). Tumor immunotherapy target and application thereof (U.S. Patent No. 11634493). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11634493

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…